Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 10:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 181 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Dry Macular Degeneration Clear all
Active, not recruiting Not applicable Interventional

Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITE III)

NCT04065490
View directory record Official record
Conditions
Dry Age-related Macular Degeneration
Interventions
Valeda PBM treatment, Valeda Sham treatment
Device
Lead sponsor
LumiThera, Inc.
Industry
Eligibility
50 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
11
States / cities
Beverly Hills, California • Palo Alto, California • Altamonte Springs, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2021 · Synced Sep 25, 2026, 10:22 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Effect of Oral Curcumin Supplementation in Dry Age-related Macular Degeneration (AMD) Patients

NCT04590196
View directory record Official record
Conditions
Age Related Macular Degeneration
Interventions
Longvida curcumin, placebo
Drug · Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
50 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Sep 25, 2026, 10:22 AM EDT
Not listed Phase 2Phase 3 Interventional

Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITEIIIB)

NCT06229665
View directory record Official record
Conditions
Dry Age-related Macular Degeneration
Interventions
Valeda Light Delivery System
Device
Lead sponsor
LumiThera, Inc.
Industry
Eligibility
50 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
7
States / cities
Beverly Hills, California • Palo Alto, California • Altamonte Springs, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced Sep 25, 2026, 10:22 AM EDT
Not listed Phase 1Phase 2 Interventional

Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration

NCT05380492
View directory record Official record
Conditions
Age-related Macular Degeneration, Geographic Atrophy
Interventions
VOY-101
Biological
Lead sponsor
Perceive Biotherapeutics, Inc.
Industry
Eligibility
50 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
Boston, Massachusetts • Bellaire, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 10, 2024 · Synced Sep 25, 2026, 10:22 AM EDT
Recruiting Phase 2 Interventional

A Phase IIb Randomized, Multicenter Trial of Subretinal CPCB-RPE1 in Advanced Dry AMD (Geographic Atrophy)

NCT06557460
View directory record Official record
Conditions
Dry Age-related Macular Degeneration, Geographic Atrophy
Interventions
Surgical implantation of the CPCB-RPE1 implant
Device
Lead sponsor
Regenerative Patch Technologies, LLC
Industry
Eligibility
55 Years to 90 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2040
U.S. locations
5
States / cities
Huntington Beach, California • Los Angeles, California • Lemont, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Sep 25, 2026, 10:22 AM EDT
Terminated No phase listed Observational

A Study of Disease Progression in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

NCT02479386
View directory record Official record
Conditions
Geographic Atrophy
Interventions
No intervention
Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
23
States / cities
Springdale, Arkansas • Campbell, California • Glendale, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 25, 2026, 10:22 AM EDT
Recruiting No phase listed Observational

Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration

NCT06375239
View directory record Official record
Conditions
Retinitis Pigmentosa, Choroideremia, Stargardt Macular Dystrophy, Stargardt Disease, Geographic Atrophy from Age-related Macular Degeneration, X-lined Retinoschisis, Retinal Dystrophies
Interventions
Not listed
Lead sponsor
Ray Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Sep 25, 2026, 10:22 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Study to Evaluate the Safety and Efficacy of Intravitreal Administration of BS01 in Patients With Geographic Atrophy Secondary to Dry AMD

NCT07158775
View directory record Official record
Conditions
Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (AMD)
Interventions
BS01, Sham procedure control
Biological · Other
Lead sponsor
Bionic Sight LLC
Industry
Eligibility
50 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Edison, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 25, 2026, 10:22 AM EDT
Completed No phase listed Observational

Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Patients With AMD

NCT02463344
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
MA09-hRPE
Biological
Lead sponsor
Astellas Institute for Regenerative Medicine
Industry
Eligibility
55 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
4
States / cities
Los Angeles, California • Miami, Florida • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Sep 25, 2026, 10:22 AM EDT
Recruiting Phase 1 Interventional

Phase 1 Study of C.001 in Retinal Degeneration

NCT07594236
View directory record Official record
Conditions
Geographic Atrophy, Stargardt Disease, RPE-mediated Maculopathy, Age Related Macular Degeneration
Interventions
Injection
Biological
Lead sponsor
Cellio Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Beverly Hills, California • Palo Alto, California • Sacramento, California
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 25, 2026, 10:22 AM EDT
Completed Phase 1 Interventional

Pharmacokinetic and Pharmacodynamic Study of Emixustat in Subjects With Geographic Atrophy Associated With Dry Age-Related Macular Degeneration

NCT02130531
View directory record Official record
Conditions
Geographic Atrophy, Age-Related Macular Degeneration
Interventions
Emixustat HCl Tablet, Placebo Tablet
Drug · Other
Lead sponsor
Kubota Vision Inc.
Industry
Eligibility
65 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 17, 2016 · Synced Sep 25, 2026, 10:22 AM EDT
Withdrawn Phase 1 Interventional

A Phase I Open Label Dose Escalation Trial of RNA-144101 in the Treatment of Geographic Atrophy

NCT01093170
View directory record Official record
Conditions
Geographic Atrophy
Interventions
RNA-144101
Drug
Lead sponsor
Mark Kleinman
Other
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 16, 2018 · Synced Sep 25, 2026, 10:22 AM EDT
Completed Phase 3 Interventional

An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD

NCT04770545
View directory record Official record
Conditions
Geographic Atrophy Secondary to Age-related Macular Degeneration
Interventions
PEGCETACOPLAN (APL-2)
Drug
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
60 Years and older
Enrollment
792 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
99
States / cities
Phoenix, Arizona • Bakersfield, California • Campbell, California + 82 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 25, 2026, 10:22 AM EDT
Completed Phase 3 Interventional Results available

Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration

NCT03525600
View directory record Official record
Conditions
Geographic Atrophy
Interventions
APL-2, Sham Procedure
Drug · Other
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
60 Years and older
Enrollment
621 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
73
States / cities
Phoenix, Arizona • Arcadia, California • Bakersfield, California + 61 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2023 · Synced Sep 25, 2026, 10:22 AM EDT
Terminated No phase listed Observational

Long-Term Follow-up Safety Study of Human Central Nervous System Stem Cells in Subjects With Geographic Atrophy of Age-Related Macular Degeneration

NCT02137915
View directory record Official record
Conditions
Age-Related Macular Degeneration, Geographic Atrophy
Interventions
Human Central Nervous System Stem Cells
Biological
Lead sponsor
StemCells, Inc.
Industry
Eligibility
51 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 1, 2016 · Synced Sep 25, 2026, 10:22 AM EDT
Terminated Phase 3 Interventional Results available

Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)

NCT02745119
View directory record Official record
Conditions
Geographic Atrophy
Interventions
Lampalizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Not listed
Enrollment
994 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
122
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 103 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Sep 25, 2026, 10:22 AM EDT
Completed Phase 2 Interventional

QA102 Phase II Study in Subjects With Dry AMD

NCT05536752
View directory record Official record
Conditions
Dry Age-related Macular Degeneration
Interventions
QA102/Placebo, QA102, Placebo
Drug
Lead sponsor
Smilebiotek Zhuhai Limited
Industry
Eligibility
50 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Plano, Texas
Source: ClinicalTrials.gov public record
Updated Jan 6, 2025 · Synced Sep 25, 2026, 10:22 AM EDT
Completed Not applicable Interventional

Study of Photobiomodulation Effect on Electroretinogram Outcomes in Dry Age-Related Macular Degeneration

NCT04522999
View directory record Official record
Conditions
Age Related Macular Degeneration
Interventions
Photobiomodulation
Device
Lead sponsor
LumiThera, Inc.
Industry
Eligibility
50 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New Port Richey, Florida
Source: ClinicalTrials.gov public record
Updated Sep 1, 2021 · Synced Sep 25, 2026, 10:22 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Evaluation of the Precision of the Microperimetry Function of the Spectral OCT/SLO

NCT01692938
View directory record Official record
Conditions
Age-Related Macular Degeneration, Geographic Atrophy, Diabetic Retinopathy, Macular Edema, Retinal Vein Occlusion, Central Serous Retinopathy, Pattern Dystrophy of Macula, Epiretinal Membrane, Macular Hole
Interventions
Not listed
Lead sponsor
Optos, PLC
Industry
Eligibility
21 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
3
States / cities
Fort Lauderdale, Florida • Baltimore, Maryland • McAllen, Texas
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Sep 25, 2026, 10:22 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Association of Macular Pigment Optical Density (MPOD) and Genetic Variants in Complement Factor H in Subjects With Choroidal Neovascular (CNV)

NCT01682382
View directory record Official record
Conditions
Age-related Macular Degeneration, Choroidal Neovascular Age-related Macular Degeneration
Interventions
Not listed
Lead sponsor
Sequenom, Inc.
Industry
Eligibility
60 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Encinitas, California
Source: ClinicalTrials.gov public record
Updated Jan 19, 2014 · Synced Sep 25, 2026, 10:22 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

NCT07160179
View directory record Official record
Conditions
Geographic Atrophy, Age-Related Macular Degeneration
Interventions
ABBV-6628, SYFOVRE
Drug
Lead sponsor
AbbVie
Industry
Eligibility
50 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
5
States / cities
Carmel, Indiana • Reno, Nevada • Abilene, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 25, 2026, 10:22 AM EDT
Recruiting No phase listed Observational

Central micrOperimetry and Radial OCT Evaluation in Geographic Atrophy (CORE-GA): a Prospective Pilot Study

NCT07556406
View directory record Official record
Conditions
Age-Related Macular Degeneration, Geographic Atrophy
Interventions
Optical coherence tomography, Microperimetry
Diagnostic Test
Lead sponsor
University of California, San Francisco
Other
Eligibility
55 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 25, 2026, 10:22 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Alpha Lipoic Acid in Geographic Atrophy

NCT02613572
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
alpha lipoic acid, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
55 Years to 90 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
5
States / cities
Iowa City, Iowa • Teaneck, New Jersey • Eugene, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Sep 25, 2026, 10:22 AM EDT
Completed Phase 2 Interventional Results available

A Study of NGM621 in Participants With Geographic Atrophy

NCT04465955
View directory record Official record
Conditions
Geographic Atrophy
Interventions
NGM621, Sham Comparator
Biological · Other
Lead sponsor
NGM Biopharmaceuticals, Inc
Industry
Eligibility
55 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
65
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 59 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2025 · Synced Sep 25, 2026, 10:22 AM EDT